DE60333500D1 - Verfahren zur Identifizierung antigener Peptide - Google Patents
Verfahren zur Identifizierung antigener PeptideInfo
- Publication number
- DE60333500D1 DE60333500D1 DE60333500T DE60333500T DE60333500D1 DE 60333500 D1 DE60333500 D1 DE 60333500D1 DE 60333500 T DE60333500 T DE 60333500T DE 60333500 T DE60333500 T DE 60333500T DE 60333500 D1 DE60333500 D1 DE 60333500D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- antigenic peptides
- utilized
- sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000000890 antigenic effect Effects 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02022223 | 2002-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60333500D1 true DE60333500D1 (de) | 2010-09-02 |
Family
ID=32116218
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60320196T Expired - Lifetime DE60320196T2 (de) | 2002-10-02 | 2003-09-24 | Verfahren zur Identifizierung antigener Peptide |
DE60333500T Expired - Lifetime DE60333500D1 (de) | 2002-10-02 | 2003-09-24 | Verfahren zur Identifizierung antigener Peptide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60320196T Expired - Lifetime DE60320196T2 (de) | 2002-10-02 | 2003-09-24 | Verfahren zur Identifizierung antigener Peptide |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040086521A1 (de) |
EP (3) | EP1405862B1 (de) |
JP (3) | JP4620339B2 (de) |
AT (2) | ATE474851T1 (de) |
AU (1) | AU2003248438A1 (de) |
CA (1) | CA2441690C (de) |
DE (2) | DE60320196T2 (de) |
ES (1) | ES2346574T3 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE442377T1 (de) * | 2003-08-07 | 2009-09-15 | Hoffmann La Roche | Ra antigene peptide |
EP1715343B1 (de) | 2005-04-20 | 2009-12-09 | F. Hoffmann-La Roche Ag | Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika |
ES2334936T3 (es) * | 2005-04-20 | 2010-03-17 | F. Hoffmann-La Roche Ag | Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos. |
JPWO2007055283A1 (ja) * | 2005-11-10 | 2009-04-30 | Jsr株式会社 | 核内受容体タンパク質複合体のプロテオミクス解析方法 |
US20100086938A1 (en) * | 2006-11-29 | 2010-04-08 | Takashi Shimada | Mass spectrometry of biological sample using immunoprecipitation |
ES2663662T3 (es) * | 2008-01-18 | 2018-04-16 | President And Fellows Of Harvard College | Métodos para detectar distintivos de enfermedades o afecciones en fluidos corporales |
JP5823379B2 (ja) * | 2009-05-29 | 2015-11-25 | ノバルティス アーゲー | インフルエンザウイルスヘマグルチニンについてのアッセイ |
WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
US20130184178A1 (en) | 2010-07-23 | 2013-07-18 | President And Fellows Of Harvard College | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions |
WO2013150680A1 (ja) * | 2012-04-06 | 2013-10-10 | 独立行政法人産業技術総合研究所 | プロテインタグ、タグ化タンパク質及びタンパク質精製方法 |
WO2014164366A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting cancer |
EP3152574A4 (de) * | 2014-06-06 | 2017-12-06 | Singapore Health Services Pte Ltd | Verfahren zur verwendung von zellen in zusammenhang mit einer autoimmunkrankheit |
KR101831483B1 (ko) | 2014-06-17 | 2018-02-23 | 이화여자대학교 산학협력단 | Mhc-페리틴 결합체, 이를 포함하는 나노파티클 및 이의 용도 |
US10718781B2 (en) | 2014-07-14 | 2020-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method for identifying epitope on protein |
WO2016079143A1 (de) | 2014-11-17 | 2016-05-26 | Pharis Biotec Gmbh | Inhibitor der viralen hepatitis c infektion |
CN105928771B (zh) * | 2016-04-08 | 2019-01-18 | 西藏恒久投资有限公司 | 一种检测疫苗抗原含量的样品前处理方法 |
CN110118845A (zh) * | 2018-02-06 | 2019-08-13 | 北京金则医学科技发展有限公司 | 检测多种氨基酸和酰基肉碱、甲基丙二酸的方法和试剂盒 |
JP6712369B2 (ja) * | 2018-05-29 | 2020-06-24 | 株式会社森永生科学研究所 | 抗ペプチド抗体の製造方法及び設計方法 |
US11603565B2 (en) * | 2018-06-15 | 2023-03-14 | Roche Sequencing Solutions, Inc. | System for identification of antigens recognized by T cell receptors expressed on tumor infiltrating lymphocytes |
WO2020037046A1 (en) * | 2018-08-14 | 2020-02-20 | Board Of Regents, The University Of Texas System | Single molecule sequencing peptides bound to the major histocompatibility complex |
CN113167796A (zh) * | 2018-09-11 | 2021-07-23 | 朱诺治疗学股份有限公司 | 对工程化细胞组合物进行质谱分析的方法 |
JP2021047198A (ja) * | 2020-12-04 | 2021-03-25 | Karydo TherapeutiX株式会社 | 心筋梗塞、認知症、および腫瘍からなる群から選択される一種を予防、または治療するための有効成分の候補物質のスクリーニング装置、スクリーニングプログラム、およびスクリーニング方法 |
CN113406240B (zh) * | 2021-07-02 | 2023-03-24 | 杭州艾儿默细胞生物科技有限公司 | 检测pHLA复合物中抗原肽的超滤-高效液相色谱法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017540A (en) * | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
WO2000005249A2 (en) * | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
EP1098902A4 (de) * | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | Behandlung von autoimmunkrankheiten mittels copolymer 1 und ähnlichen copolymeren und peptiden |
WO2002040647A1 (en) * | 2000-11-14 | 2002-05-23 | U.S. Army Medical Research Institute Of Infectious Diseases | Method of establishing cultures of human dendritic cells and use thereof |
-
2003
- 2003-09-24 EP EP03021521A patent/EP1405862B1/de not_active Expired - Lifetime
- 2003-09-24 DE DE60320196T patent/DE60320196T2/de not_active Expired - Lifetime
- 2003-09-24 EP EP07011493A patent/EP1826217B1/de not_active Expired - Lifetime
- 2003-09-24 AT AT07011493T patent/ATE474851T1/de not_active IP Right Cessation
- 2003-09-24 AT AT03021521T patent/ATE391723T1/de not_active IP Right Cessation
- 2003-09-24 DE DE60333500T patent/DE60333500D1/de not_active Expired - Lifetime
- 2003-09-24 EP EP06015737A patent/EP1714981A3/de not_active Withdrawn
- 2003-09-24 ES ES07011493T patent/ES2346574T3/es not_active Expired - Lifetime
- 2003-09-25 CA CA2441690A patent/CA2441690C/en not_active Expired - Lifetime
- 2003-09-26 AU AU2003248438A patent/AU2003248438A1/en not_active Abandoned
- 2003-10-01 US US10/676,909 patent/US20040086521A1/en not_active Abandoned
- 2003-10-02 JP JP2003343918A patent/JP4620339B2/ja not_active Expired - Lifetime
-
2007
- 2007-04-05 JP JP2007098939A patent/JP2007211020A/ja active Pending
-
2010
- 2010-09-22 JP JP2010211787A patent/JP2011012073A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2011012073A (ja) | 2011-01-20 |
EP1826217A1 (de) | 2007-08-29 |
EP1714981A3 (de) | 2006-12-20 |
EP1405862A3 (de) | 2004-06-09 |
JP2004123749A (ja) | 2004-04-22 |
EP1405862A2 (de) | 2004-04-07 |
EP1714981A2 (de) | 2006-10-25 |
DE60320196T2 (de) | 2009-05-14 |
CA2441690C (en) | 2011-08-02 |
US20040086521A1 (en) | 2004-05-06 |
AU2003248438A1 (en) | 2004-04-22 |
CA2441690A1 (en) | 2004-04-02 |
EP1826217B1 (de) | 2010-07-21 |
DE60320196D1 (de) | 2008-05-21 |
JP4620339B2 (ja) | 2011-01-26 |
EP1405862B1 (de) | 2008-04-09 |
ES2346574T3 (es) | 2010-10-18 |
ATE391723T1 (de) | 2008-04-15 |
ATE474851T1 (de) | 2010-08-15 |
JP2007211020A (ja) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60320196D1 (de) | Verfahren zur Identifizierung antigener Peptide | |
ES2836273T3 (es) | Método para el tratamiento del cáncer | |
KR102447139B1 (ko) | 종양 특이적 신생항원을 확인하는 조성물 및 방법 | |
US10550430B2 (en) | Method and kit for determining whether a subject shows an immune response | |
WO2003106692A3 (en) | METHODS OF IDENTIFYING ALLO-ANTIGENS AND THEIR USE IN CANCER THERAPY AND TRANSPLANTATION | |
ES2537323T3 (es) | Péptido CDCA1 y agente farmacéutico que lo comprende | |
EP3004137B1 (de) | Verbessertes verfahren zur detektion, zubereitung und abreicherung von cd4+ t lymphozyten | |
CA3049456A1 (en) | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes | |
DK1759013T3 (da) | Identificering af overflade-associerede antigener til tumordiagnose | |
US20170146526A1 (en) | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs | |
CA2715536A1 (en) | Cd4+ t-cells with cytolytic properties | |
CN113015542A (zh) | 具有改善的氧化还原酶基序的免疫原性肽 | |
JP2021534830A (ja) | 腫瘍特異的抗原を特定するためのプロテオゲノミクスに基づいた方法 | |
Beckhove et al. | Rapid T cell–based identification of human tumor tissue antigens by automated two-dimensional protein fractionation | |
US20230098624A1 (en) | Methods and vaccines for inducing immune responses to multiple different mhc molecules | |
WO2006102901A3 (en) | Immunogenic egfr peptides comprising foreign t cell stimulating epitope | |
JP2009500036A (ja) | 非ゼロバックグラウンドのペプチドによる免疫応答レベルの安定な定量化及び検出 | |
ES2353964T3 (es) | Procedimiento para la inmunoterapia de tumores. | |
JP2022532409A (ja) | 改変されたシステインを含む酸化還元酵素モチーフを有する免疫原性ペプチド | |
Scheibenbogen et al. | Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides | |
JPWO2005105993A1 (ja) | Hla結合性ペプチド、その前駆体、それをコードするdna断片および組み換えベクター | |
EP3600401A1 (de) | Rekombinante chlamydia-aktivierte b-zellplattformen und anwendungsverfahren dafür | |
RU2650872C1 (ru) | Искусственный ген MEL-TCI, кодирующий полиэпитопный белок-иммуноген MEL-TCI, рекомбинантная плазмидная ДНК pMEL-TCI, обеспечивающая экспрессию искусственного гена MEL-TCI и искусственный белок-иммуноген MEL-TCI, содержащий CTL- и Th-эпитопы антигенов меланомы, рестриктированные множественными аллелями HLA I и II класса | |
NAIM | Gold-nanocluster-mediated microinflammation detection using a tissue clearing method and Molecular mechanism for SARS-CoV-2-specific CD4+ T cell activation in healthy people | |
RU2005100758A (ru) | Способ картирования и устранения эпитопов т-клеток |